Drug Patents owned by Bausch And Lomb Inc
1. Drug name - BEPREVE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8877168 | BAUSCH AND LOMB INC | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
Jul, 2023
(9 months from now) | |
| US8784789 | BAUSCH AND LOMB INC | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
Jan, 2025
(2 years from now) | |
Drugs and Companies using BEPOTASTINE BESILATE ingredient
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 1.5% | SOLUTION/DROPS;OPHTHALMIC | Prescription |
2. Drug name - LOTEMAX SM
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10596107 | BAUSCH AND LOMB INC | Ophthalmic suspension composition |
Dec, 2036
(14 years from now) | |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Treatment: Treatment of post-operative inflammation and pain following ocular surgery
Dosage: GEL;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 0.38% | GEL;OPHTHALMIC | Prescription |
3. Drug name - LUMIFY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9259425 | BAUSCH AND LOMB INC | Compositions and methods for eye whitening |
Jul, 2030
(7 years from now) | |
| US8293742 | BAUSCH AND LOMB INC | Preferential vasoconstriction compositions and methods of use |
Jul, 2030
(7 years from now) | |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Treatment: Relieves redness of the eye due to minor eye irritations
Dosage: SOLUTION/DROPS;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 0.025% | SOLUTION/DROPS;OPHTHALMIC | Over the counter |
4. Drug name - XIPERE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8636713 | BAUSCH AND LOMB INC | Methods and devices for drug delivery to ocular tissue using microneedle |
May, 2027
(4 years from now) | |
| US9636332 | BAUSCH AND LOMB INC | Methods and devices for the treatment of ocular diseases in human subjects |
Nov, 2033
(11 years from now) | |
| US9937075 | BAUSCH AND LOMB INC | Apparatus and methods for ocular injection |
May, 2034
(11 years from now) | |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Treatment: Treatment of macular edema associated with uveitis
Dosage: SUSPENSION;INJECTION
| Strength | Dosage | Availability |
|---|---|---|
| 40MG/ML | SUSPENSION;INJECTION | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.